{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:34:23Z","timestamp":1792978463777,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CFRPG3L0031"],"award-info":[{"award-number":["CFRPG3L0031"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CFRPG3K0041"],"award-info":[{"award-number":["CFRPG3K0041"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC-MOST105-2628-B-182A-007-MY3"],"award-info":[{"award-number":["NSC-MOST105-2628-B-182A-007-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eprac.2024.01.016","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T20:21:01Z","timestamp":1707164461000},"page":"424-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A\u00a0Nationwide Population-Based Study"],"prefix":"10.1016","volume":"30","author":[{"given":"Yi-Hsuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Shun","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-2354","authenticated-orcid":false,"given":"Sheng-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2024.01.016_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J\u00a0Diabetes Investig"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.016_bib2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.eprac.2024.01.016_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.016_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2024.01.016_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2024.01.016_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154936","article-title":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","volume":"127","author":"Marfella","year":"2022","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.eprac.2024.01.016_bib7","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/biomedicines9101356","article-title":"Cardiovascular benefits from gliflozins: effects on endothelial function","volume":"9","author":"Salvatore","year":"2021","journal-title":"Biomedicines"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2024.01.016_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A\u00a0review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2024.01.016_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib10","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2024.01.016_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.eprac.2024.01.016_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.016_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/07853890.2016.1231932","article-title":"Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis \u2020","volume":"49","author":"Zhang","year":"2017","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000795","article-title":"Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period","volume":"7","author":"Lin","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"10.1016\/j.eprac.2024.01.016_bib15","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s00125-012-2673-3","article-title":"The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis","volume":"55","author":"Brownrigg","year":"2012","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","article-title":"Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer","volume":"13","author":"Armstrong","year":"2020","journal-title":"J\u00a0Foot Ankle Res"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.016_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/ijem.ijem_237_21","article-title":"Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis","volume":"25","author":"Dalui","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.01.016_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4103\/ijem.IJEM_104_18","article-title":"A\u00a0review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors","volume":"22","author":"Khalse","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.eprac.2024.01.016_bib19","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2024.01.016_bib20","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.01.016_bib21","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.jcjd.2017.10.026","article-title":"Treatment of diabetes in people with heart failure","volume":"42","author":"Connelly","year":"2018","journal-title":"Can J Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2024.01.016_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","article-title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes","volume":"62","author":"Garg","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.eprac.2024.01.016_bib23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1534734605280130","article-title":"A\u00a0review of the mechanisms implicated in the pathogenesis of the diabetic foot","volume":"4","author":"Dinh","year":"2005","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.22.1.157","article-title":"Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings","volume":"22","author":"Reiber","year":"1999","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2024.01.016_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jdiacomp.2012.05.015","article-title":"Epigenetic mechanisms in the pathogenesis of diabetic foot ulcers","volume":"26","author":"Rafehi","year":"2012","journal-title":"J\u00a0Diabetes Complications"},{"issue":"10166","key":"10.1016\/j.eprac.2024.01.016_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.016_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgrad Med"},{"issue":"10","key":"10.1016\/j.eprac.2024.01.016_bib28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2024.01.016_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","article-title":"SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis","volume":"22","author":"Sardu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biomedicines9010003","article-title":"Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects?","volume":"9","author":"Salvatore","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.eprac.2024.01.016_bib33","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.01.016_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.eprac.2024.01.016_bib35","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eprac.2024.01.016_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.17925\/USE.2020.16.2.80","article-title":"Clinical evidence and proposed mechanisms for cardiovascular and kidney benefits from glucagon-like peptide-1 receptor agonists","volume":"16","author":"Cox","year":"2020","journal-title":"US Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.eprac.2024.01.016_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.13888","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials","volume":"22","author":"Mannucci","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-020-01049-w","article-title":"Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice","volume":"19","author":"Longato","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2024.01.016_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-018-0778-9","volume":"17","author":"Sardu","year":"2018","journal-title":"Cardiovasc Diabetol"}],"updated-by":[{"DOI":"10.1016\/j.eprac.2024.06.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:57:42Z","timestamp":1762549062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1530891X24000624"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.01.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A\u00a0Nationwide Population-Based Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}